Pre Exposure Prophylaxis News and Research

RSS

Study reveals substantial gap in PrEP access in more than one-third of New England colleges and universities

Young gay, bisexual, and other men who have sex with men (MSM), accounted for 80% of new HIV infections among youth ages 13–24 in 2018 and represents a priority population for HIV prevention.

24 Jul 2023

Could neutralizing SARS-CoV-2 monoclonal antibodies pre-exposure prophylaxis be cost-effective in a population at risk for severe COVID-19?

A recent study evaluated the cost-effectiveness of monoclonal antibodies as pre-exposure prophylaxis (PrEP) for COVID-19.

11 Jul 2023

Antiretroviral treatment efficiently suppresses penile HIV replication

Of the 38 million people worldwide living with HIV, approximately 700,000 are newly infected men, primarily via sexual transmission.

12 Jun 2023

Real-world assessment of JYNNEOS vaccine effectiveness during the 2022 mpox outbreak in the US

A recent study published in Morbidity and Mortality Weekly Report estimated the efficacy of the JYNNEOS vaccine against mpox.

22 May 2023

Understanding the adverse events profile of MVA-BN vaccine for Mpox

Researchers evaluated adverse events following the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccination for mpox.

10 May 2023

Post-exposure doxycycline approach leads to two-thirds reduction in STI incidence

The oral antibiotic doxycycline prevented the acquisition of sexually transmitted infections (STIs) when tested among men who have sex with men (MSM) and transgender women who took the medication within 72 hours of having condomless sex, according to findings published today in the New England Journal of Medicine.

6 Apr 2023

Study examines parental concerns of their sexual and gender minority adolescents using PrEP

Since its approval in 2012, HIV pre-exposure prophylaxis, or PrEP, has shown promise in reducing HIV infection rates by preventing infection in high-risk HIV-negative people.

2 Mar 2023

Use of dapivirine vaginal ring during third trimester of pregnancy poses no safety concerns

A vaginal ring containing the antiretroviral drug dapivirine posed no safety concerns when used in the third trimester of pregnancy, according to results to date from the first study of the dapivirine ring during pregnancy and one of only a few studies of an HIV prevention product in pregnant cisgender women.

20 Feb 2023

Doxycycline taken after sex does not prevent bacterial STIs among cisgender women

Researchers from the University of Washington (UW), Kenya Medical Research Institute (KEMRI), and Hennepin Healthcare Research Institute (HHRI) announced results at CROI from a clinical trial demonstrating that doxycycline taken after sex does not prevent bacterial sexually transmitted infections (STIs) – chlamydia or gonorrhea – among cisgender women.

20 Feb 2023

HIV prevention model in Zambian prisons may be extended to other criminal justice facilities

A recent study performed in Zambia by University of Maryland School of Medicine's Institute of Human Virology researchers found that high uptake of HIV preventative medicine, known as pre-exposure prophylaxis (PrEP), is possible in prison populations with adequate resources and support from the criminal justice health system.

16 Feb 2023

New formulation can provide up to six months of full protection against HIV

For people at high risk of contracting HIV, missing doses of their daily HIV prevention pills can have big consequences. In some cases, missing a pill can lead to lack of protection against the virus.

9 Feb 2023

Side-effects and costs are important issues for users of HIV pre-exposure prophylaxis, survey finds

A new survey finds that men who would be potential users of HIV pre-exposure prophylaxis (PrEP) medication prefer long-acting injections over pills, but rank side effects and costs as the most important issues for them in considering whether to take PrEP.

1 Feb 2023

A slight increase in Mpox cases across the globe, along with an increase in deaths

The WHO discusses genomic sequencing of the Mpox virus, in addition to providing public and clinical health links between HIV and Mpox.

24 Jan 2023

WHO’s 14th situation report for the multi-country outbreak of mpox overviews the clinical and public health links between HIV and mpox

In the present report, researchers reported the most recent findings of MPXV infections.

23 Jan 2023

Investigational vaccine regimen safe but did not provide protection against HIV acquisition

An investigational HIV vaccine regimen tested among men who have sex with men (MSM) and transgender people was safe but did not provide protection against HIV acquisition, an independent data and safety monitoring board (DSMB) has determined.

18 Jan 2023

What are the characteristics of misdiagnosed human mpox cases?

In a recent study, researchers characterized overlooked cases of monkeypox (MPX).

21 Dec 2022

Medicaid expansion and increase in PrEP, antiretroviral treatment could result in decline of new HIV infections

Enacting Medicaid expansion in Texas and increasing the use of preventive and antiviral medications could result in a decline of new HIV infections among young Black gay, bisexual, and other men who have sex with men (MSM) in Houston, reports a study in the January issue of Medical Care. The journal is published in the Lippincott portfolio by Wolters Kluwer.

13 Dec 2022